Hydrazonopyrazole derivatives and their use as therapeutics
Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ic):
as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof;
wherein:
R 1c is hydrogen, alkyl, aryl or aralkyl;
R 2c is aryl optionally substituted with one or more substituents selected from the group consisting of fluoro, —R 6c —N(R 8c ) 2 , —S(O) 2 —R 6c —OH, —S(O) 2 —N(R 7c )R 8c and heterocyclylalkyl;
R 4c is hydrogen or alkyl;
R 3c is hydrogen, alkyl, heterocyclylalkyl, or heterocyclylcarbonyl;
R 5c is alkyl, alkenyl, cycloalkyl (optionally substituted by one or more substituents selected from the group consisting of alkyl and aryl);
each R 6c is independently a straight or branched alkylene chain;
each R 7c is independently hydrogen, alkyl, aryl, aralkyl or heterocyclylalkyl;
R 8c is hydrogen, alkyl, aryl aralkyl or hydroxyalkyl,
provided that when R 1c , R 3c and R 4c are all hydrogen and R 5c is methyl, R 2c can not be phenyl optionally substituted with one or more substituents selected from the group consisting of chloro, bromo or alkyl.
2. The pharmaceutical composition of claim 1 wherein the compound is a compound of formula (Ic) wherein:
R 2c is phenyl optionally substituted with one or more substituents selected from the group consisting of fluoro, —R 6c —N(R 8c ) 2 , —S(O) 2 —R 6c —OH, —S(O) 2 —N(R 7c )R 8c and heterocyclylalkyl; and
R 5c is alkyl, alkenyl, cycloalkyl (optionally substituted by one or more substituents selected from the group consisting of alkyl and phenyl).
3. The pharmaceutical composition of claim 2 wherein the compound is a compound of formula (Ic) selected from the group consisting of the following:
tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine;
4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine
5-tert-butyl-4-[(3-fluorophenyl)hydrazono]-4H-pyrazol-3-ylamine;
5-but-3-enyl-4-[(3,4-difluorophenyl)hydrazono]-4H-pyrazol-3-ylamine;
4-[(3,4-difluorophenyl)hydrazono]-5-methyl-4H-pyrazol-3-ylamine;
{4-[(3,4-difluorophenyl)hydrazono]-5-methyl-4H-pyrazol-3-yl}ethylamine;
5-ethyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
ethyl-{4-[(3-fluoro-phenyl)hydrazono]-5-methyl-4H-pyrazol-3-yl}amine;
{4-[(3,4-difluorophenyl)hydrazono]-5-methyl-4H-pyrazol-3-yl}methylamine;
5-cyclopropyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-isopropyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-(2,2-dimethylpropyl)-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-(2-phenylcyclopropyl)-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-(1-ethylpropyl)-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-isobutyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
{4-[(3-fluorophenyl)-hydrazono]-5-methyl-4H-pyrazol-3-yl}methylamine;
3-[N′-(3-amino-5-cyclopropylpyrazol-4-ylidene)hydrazino]-n-(2-hydroxyethyl)-benzenesulfonamide;
3-[N′-(3-amino-5-cyclopropylpyrazol-4-ylidene)hydrazino]benzenesulfonamide;
and 3-[N′-(3-Amino-5-cyclopropylpyrazol-4-ylidene)hydrazino]-N-methylbenzenesulfonamide.
4. A compound of formula (Ic):
as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof;
wherein:
R 1c is hydrogen, alkyl, aryl or aralkyl;
R 2c is aryl optionally substituted with one or more substituents selected from the group consisting of fluoro, —R 6c —N(R 8c ) 2 , —S(O) 2 —R 6c —OH, —S(O) 2 —N(R 7c )R 8c and heterocyclylalkyl;
R 3c is hydrogen, alkyl, heterocyclylalkyl, or heterocyclylcarbonyl;
R 4c is hydrogen or alkyl;
R 5c is alkyl, alkenyl, or cycloalkyl (optionally substituted by one or more substituents selected from the group consisting of alkyl and phenyl);
R 6c is a straight or branched alkylene chain;
R 7c is hydrogen, alkyl, aryl, aralkyl or heterocyclylalkyl; and
R 8c is hydrogen, alkyl, aryl, aralkyl or hydroxyalkyl,
provided that when R 1c , R 3c and R 4c are all hydrogen and R 5c is methyl, R 2c can not be phenyl optionally substituted with one or more substituents selected from the group consisting of chloro, bromo or alkyl.
5. The compound of claim 4 selected from the group consisting of the following:
tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine;
4-(3-fluorophenylazo)-5-methyl-2H-pyrazol-3-ylamine;
5-tert-butyl-4-[(3-fluorophenyl)hydrazono]-4H-pyrazol-3-ylamine;
5-but-3-enyl-4-[(3,4-difluorophenyl)hydrazono]-4H-pyrazol-3-ylamine;
4-[(3,4-difluorophenyl)hydrazono]-5-methyl-4H-pyrazol-3-ylamine;
{4-[(3,4-difluorophenyl)hydrazono]-5-methyl-4H-pyrazol-3-yl}ethylamine;
5-ethyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
ethyl-{4-[(3-fluoro-phenyl)hydrazono]-5-methyl-4H-pyrazol-3-yl}amine;
{4-[(3,4-difluorophenyl)hydrazono]-5-methyl-4H-pyrazol-3-yl}methylamine;
5-cyclopropyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-isopropyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-(2,2-dimethylpropyl)-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-(2-phenylcyclopropyl)-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-(1-ethylpropyl)-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
5-isobutyl-4-(phenylhydrazono)-4H-pyrazol-3-ylamine;
{4-[(3-fluorophenyl)-hydrazono]-5-methyl-4H-pyrazol-3-yl}methylamine;
3-[N′-(3-Amino-5-cyclopropylpyrazol-4-ylidene)hydrazino]-N-methylbenzenesulfonamide;
3-[N′-(3-amino-5-cyclopropylpyrazol-4-ylidene)hydrazino]-N-(2-hydroxyethyl)benzene-sulfonamide; and
3-[N′-(3-amino-5-cyclopropylpyrazol-4-ylidene)hydrazino]benzenesulfonamide.